Author(s)

Juan C. Fernandez-Guerrero, Juan A. Herrador, Manuel Guzman, Victor Aragon, Carmen Adamuz

Unidad de Hemodinámica, Servicio de Cardiología, Complejo Hospitalario de Jaén, Jaén, Spain.

Objectives: We sought to evaluate the efficacy and safety of unrestricted implantation of everolimus eluting stent Xience V (EES-XV) in a cohort of real- world patients with unprotected left main coronary disease (ULMCD). Background: The second-generation EES-XV stent is currently one of the most commonly used drug-eluting stents in clinical practice. It has been shown to be superior to paclitaxel-eluting stents, but its relative merits on unprotected left main coronary disease have been less extensively assessed. Methods: Between 2007 and 2010, in this single-center registry, we evaluated the clinical outcomes of 98 patients with ULMCD who underwent percutaneous coronary intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At 25.63 ± 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse coronary event (MACE), death from cardiovascular disease (n = 6; 6.1%) and target lesion revascularization (TLR; n = 7; 7.1%). The predictors of death from cardiovascular disease were: previous PCI and left ventricular dysfunction. The only predictor of TLR was the placement of 2 stents in the left main coronary artery. Conclusions: In this single- center real-world registry, we found that elective ULMCD stenting with EES-XV provided good short-, medium- and long-term outcomes, with an estimated cumulative need for TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2 years.

Percutaneous Coronary Interventions; “Off Label” Lesions; Prognosis

Fernandez-Guerrero, J. , Herrador, J. , Guzman, M. , Aragon, V. and Adamuz, C. (2013) Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience. World Journal of Cardiovascular Diseases, 3, 183-190. doi: 10.4236/wjcd.2013.32026.